

# From (Particle) Physics to Medical Applications





Photo: CNAO treatment room

# Disclaimer(s) & Acknowledgments

Of course, I had to select the material to be included.

And of course, Physics  $\neq$  HEP (but a lot of HEP here, and a lot of CERN examples).

The CERN medical applications-related projects presented in this talk are realized by the CERN scientists and engineers: without their skills, ingenuity, and dedication, there would be no knowledge to transfer! Some names are acknowledged on the respective slides, but there are many more.



The KT group and myself are privileged to have the opportunity to support these projects in a tailored way, and to help bridge the gap between CERN technologies and society.

Many thanks to all the colleagues from CERN, CNAO, CHUV, GSI, MedAustron, INFN, TERA who have shared their material and wisdom with me; thanks to Ugo Amaldi and Manjit Dosanjh, from whom I first learned about hadron therapy.

I am neither a doctor, nor a medical physicist, nor a technical expert in most of the technologies I present, so the Q&A will be fun! 😊




# The physics itself




By Original: Penubag Vector: Victor Blacus - Own work based on: Electromagnetic-Spectrum.png, CC BY-SA 3.0, <https://commons.wikimedia.org/w/index.php?curid=22428451>

# X-Rays



**1895**







Henri Becquerel

1896: accidental discovery of natural radioactivity

Mme. Curie thesis – 1904  
 $\alpha$ ,  $\beta$ ,  $\gamma$  in magnetic field



1898: by studying the strange uranium rays, they soon discovered polonium, thorium, radium



Pierre Curie and Marie Skłodowka-Curie



CRÈME  
POUDRE

SAVON  
DENTIFRICE

**THO-RADIA**  
à base de Thorium et de radium selon la formule du  
DOCTEUR ALFRED CURIE  
EN VENTE EXCLUSIVEMENT CHEZ LES PHARMACIENS

Par Cinémagazine, 14 février 1935 —  
<https://gallica.bnf.fr/ark:/12148/bpt6k2000628h>, CC BY-SA 4.0,  
<https://commons.wikimedia.org/w/index.php?curid=97956453>

12 New York Tribune November 10, 1918

# Radium and Beauty

HERE are the first toilet preparations to embody Actual Radium, an astonishing new force for betterment, applied as an aid to Beauty. Learn how the amazing Energy of Radium has proved a boon to the human skin. Learn what Radium actually means to Beauty and how its power is employed in "Radium" Preparations. Study our \$5,000 guarantee. Then turn to "Radium" Toilet Requisites. When you have used, enjoyed and tested them you will adopt them as your own first aid to Beauty.

**PREHISTORIC** women first discovered face-cream in some great jungle pool. Ever since Beauty has engaged the world's attention.

Radium, though new to the world, is no new discovery. It is the world's most abundant element. Its source has been known for centuries. It is the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements. It is the most abundant of all elements.

Who could have imagined that these two elements would come together in such a beautiful way? Radium, the most powerful of all elements, and Thorium, the most abundant of all elements, have combined to form a new and beautiful element, Radium Thorium. This new element is the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements. It is the most abundant of all elements.

The latest scientific discovery of Radium Thorium, the most powerful of all elements, has been applied to the most beautiful of all elements, Beauty. This new element is the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements. It is the most abundant of all elements.

Each and every "Radium" Beauty Aid is the result of a famous French specialist, Dr. Alfred Curie, who has been the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements.

When you use "Radium" Beauty Aids, you will find that they are the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements.

Write Today for This Vitrally Interesting Booklet

This is probably the most interesting booklet on the subject of Beauty ever published. It is the most powerful of all elements. It is the most abundant of all elements. It is the most powerful of all elements. It is the most abundant of all elements.

**RADIUM CO., LTD. of LONDON**  
235 Fifth Ave., New York

Confidence: Please mail me a copy of your booklet, "Radium and Beauty." I understand that this request places no obligation upon me.

Name \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_

**RADIUM TOILET REQUISITES**  
OBTAINABLE AT  
Leading Department Stores of  
New York, Brooklyn and Newark  
Liggett's Drug Stores

**Radium Co., Ltd., of London**  
235 Fifth Avenue, New York  
187 Oxford St., London, W. 1.  
If your Dealer cannot supply you communicate with us.

Par Radium cosmetics — sited New York Tribune Magazine,  
 page 12, Domaine public,  
<https://commons.wikimedia.org/w/index.php?curid=35047170>



Par Sam LaRussa from United States of America —  
 Radithor, CC BY-SA 2.0,  
<https://commons.wikimedia.org/w/index.php?curid=57841049>



<https://www.smh.com.au/national/nsw/from-the-archives-1956-ban-urged-of-x-ray-machines-at-shoe-shops-20210318-p57c1m.html>



## THE PHYSIOLOGICAL ACTION OF RADIO-ACTIVE SUBS





Fig. 51.

Professor Curie's arm, showing a scar resulting from a  
(Through the courtesy of the Success Company.)





X-ray apparatus used for treatment of epithelioma of the face, 1915.



Small tubes containing radium salts are strapped to a woman's face to treat what was either lupus or rodent ulcer, 1905.



## The Nobel Prize in Physics 1944



Photo from the Nobel Foundation archive.

**Isidor Isaac Rabi**

Prize share: 1/1

The Nobel Prize in Physics 1944 was awarded to Isidor Isaac Rabi "for his resonance method for recording the magnetic properties of atomic nuclei."

## The Nobel Prize in Physics 1952



Photo from the Nobel Foundation archive.

**Felix Bloch**

Prize share: 1/2



Photo from the Nobel Foundation archive.

**Edward Mills Purcell**

Prize share: 1/2

The Nobel Prize in Physics 1952 was awarded jointly to Felix Bloch and Edward Mills Purcell "for their development of new methods for nuclear magnetic precision measurements and discoveries in connection therewith."

## The Nobel Prize in Physiology or Medicine 2003



Photo from the Nobel Foundation archive.

**Paul C. Lauterbur**

Prize share: 1/2



Photo from the Nobel Foundation archive.

**Sir Peter Mansfield**

Prize share: 1/2

The Nobel Prize in Physiology or Medicine 2003 was awarded jointly to Paul C. Lauterbur and Sir Peter Mansfield "for their discoveries concerning magnetic resonance imaging."



# The technologies













Over **70** companies and institutes produce accelerators for industrial applications; these organizations sell more than **1,100 industrial systems per year** — almost twice the number produced for research or medical therapy — at a **market value of \$2.2B.**

Over **\$1B** of this amount is generated by the sales of accelerators for **ion implantation** into materials — primarily semiconductor devices — whose worldwide value of production is about **\$300B.**

Hamm,R.andHamm,M.(2012).Industrial accelerators and their applications. World Scientific Publishing Co.


As of 2014 there were **42,200** accelerators worldwide:  
**27,000 (64%)** in industry,  
**14,000 (33%)** for medical purposes  
**1,200 (3%)** for basic research.


These figures exclude electron microscopes and x-ray tubes, and the security and defense industries.

Chernyaev, A. P. and Varzar, S. M. (2014). Particle accelerators in modern world. Physics of Atomic Nuclei, 77(10):1203–1215.



Area	Application	Beam	Accelerator	Beam energy/MeV	Beam current/ mA	Number
Medical	Cancer therapy	e	linac	4-20	$10^{-2}$	>14000
		p	cyclotron, synchrotron	250	$10^{-6}$	60
		C	synchrotron	4800	$10^{-7}$	10
	Radioisotope production	p	cyclotron	8-100	1	1600
Industrial	Ion implantation	B, As, P	electrostatic	< 1	2	>11000
	Ion beam analysis	p, He	electrostatic	<5	$10^{-4}$	300
	Material processing	e	electrostatic, linac, Rhodatron	$\leq 10$	150	7500
	Sterilisation	e	electrostatic, linac, Rhodatron	$\leq 10$	10	3000
Security	X-ray screening of cargo	e	linac	4-10	?	100?
	Hydrodynamic testing	e	linear induction	10-20	1000	5
Synchrotron light sources	Biology, medicine, materials science	e	synchrotron, linac	500-10000		70
Neutron scattering	Materials science	p	cyclotron, synchrotron, linac	600-1000	2	4
Energy - fusion	Neutral ion beam heating	d	electrostatic	1	50	10
	Heavy ion inertial fusion	Pb, Cs	Induction linac	8	1000	Under development
	Materials studies	d	linac	40	125	Under development
Energy - fission	Waste burner	p	linac	600-1000	10	Under development
	Thorium fuel amplifier	p	linac	600-1000	10	Under development
Energy - bio-fuel	Bio-fuel production	e	electrostatic	5	10	Under development
Environmental	Water treatment	e	electrostatic	5	10	5
	Flue gas treatment	e	electrostatic	0.7	50	Under development





Courtesy Maurizio Vretenar

# Radiotherapy









Fig. 1. The 8 MeV linear accelerator (Metropolitan-Vickers) at Hammersmith Hospital with the angle of the roentgen head adjusted to give a beam directed vertically downwards.

1953

P. Howard-Flanders (1954) The Development of the Linear Accelerator as a Clinical Instrument, *Acta Radiologica*, 41:sup116, 649-655, DOI: 10.3109/00016925409177244



1956: The first patient to receive radiation therapy from the medical linear accelerator at Stanford was a 2-year-old boy.

Approx. date of introduction	Model and location	Manufacturer	Beam energy and modality
1953	Hammersmith Hospital, London	Metropolitan-Vickers	8 MV X-rays
1954	St. Bartholomew's Hospital, London	Mullard	15 MeV X-rays and electrons
1954	Christie Hospital, Manchester	Metropolitan-Vickers AEI	4 MV X-ray
1954	Newcastle	Mullard	4 MV X-ray
1955	Stanford	Stanford	5 MV X-ray
1955	Argonne Cancer Hospital, Chicago	Stanford, HVE and Argonne	5-50 MeV electrons
1955	Michael Reese Hospital, Chicago	Stanford, M. Reese and Helene Curtis	45 MeV electrons
1962	Newcastle	Vickers Research	4 MV X-ray
1962	Clinac 6	Varian	6 MV X-ray
1965	Mevatron 8	Applied Radiation	6-8 MV X-rays 3-10 MeV electrons
1965	SL-75	Mullard	6-8 MV X-rays 8-10 MeV electrons

Table 1 (cont.)

Approx. date of introduction	Model and location	Manufacturer	Beam energy and modality
1967	Sagittaire, Paris	CSF	16 MV X-rays 12-32 MeV electrons
1968	Clinac 4	Varian	4 MV X-rays
1969	Mevatron VI & XII	Applied Radiation	6 or 8 MV X-rays 3-11 MeV electrons
1969	LMR-13	Toshiba	8 and 10 MV X-rays 8-13 MeV electrons
1970	Therapi 4	SHM	4 MV X-rays
1970	Clinac 35 Hiroshima	Varian	8 and 25 MV X-rays 7-28 MeV

C J Karzmark and N C Pering 1973 *Phys. Med. Biol.* **18** 321

# Status of Radiation Therapy Equipment

**155** **7602**

Countries

RT Centres

**14875**

MV Therapy


## Equipment type

(Updated on : 23/06/2021 09:19:53)



## Equipment per income groups

(Updated on : 23/06/2021 09:19:53)





# Status of Radiation Therapy Equipment

**155** **7602**

Countries

RT Centres

**14875**

MV Therapy

STELLA Collaboration  
formed to address the lack  
of radiotherapy in  
challenging environments.

Supported by ICEC, UK  
STFC, Lancaster and Oxford  
University, CERN, users in  
LMICs

14,875

(Updated on : 23/06/2021 09:19:53)

High income (H) 9,365

Upper middle income (UM) 4,165


Lower middle income (LM) 1,303

Low income (L) 39

Temporarily unclassified (NC) 3





# Protons, ions: hadron therapy, particle therapy, (light, heavy) ion therapy







## X-rays



## Carbon ion beams



<https://link.springer.com/article/10.1186/1878-5085-4-9>

# How to make it better

Image-Guided Radiation Therapy

Intensity-modulated radiation therapy



MRI-guided radiation therapy

...



**Berkeley**

- 1931 Invention of cyclotron (Ernest Lawrence)
- 1946 RR Wilson published his seminal paper on particle therapy
- 1952 First biological investigation with accelerated nuclei (C Tobias and JH Lawrence)
- 1954 First therapeutic exposure of humans to protons and alphas (Tobias and JH Lawrence)
- 1975 Clinical trials with accelerated light ions at LBL (Castro)



**Gustav Werner Institute and Theodor Svedberg Laboratory**

- 1949 Synchrocyclotron at the Gustav Werner Institute (Uppsala)
- 1950s Pre-therapeutic physical experiments with high energy protons (B. Larsson)
- 1957 First patient treated with proton beam



# $\pi^-$ beam therapy

**1935** Yukawa theory on pi meson


**1947** Discovery of pions

**1951** Possibility of using negative pions for cancer therapy (Tobias and Richman)

**1961** Clinical use of  $\pi^-$  advocated (Fowler and Perkins, Nature 1961)

**‘70-’80s** Clinical trials of negative pions at LAMPF, TRIUMF, PSI and Stanford

William T. Chu  
EO Lawrence Berkeley National Laboratory  
PTCOG From 1985 to Present and Future



*In a pilot experimental program at LAMPF's Biomedical Facility, about 250 patients were treated with negative pions for a variety of advanced deep-seated tumors. Compared to conventional x-ray therapy, pion therapy is expected to provide improved dose localization and biological effectiveness. Shown positioning a patient under the pion radiotherapy beam are (left to right) Dr. Morton Kligerman, former Director of the University of New Mexico's Cancer Research and Treatment Center, a visiting radiotherapist from Japan, and Dr. Steven Bush, formerly of the University of New Mexico. The hardware at the upper right includes a beam collimator, a dose monitor, and a device for changing the penetration depth of the pions.*


LAMPF: a dream and a gamble



# From physics labs...



1932 - E. Lawrence  
First cyclotron



1946 – proton therapy  
proposed by R. Wilson




1954 – Berkeley treats  
the first patient

# ...to clinics



1989  
Clatterbridge UK




1990  
Loma Linda USA



1994  
HIMAC Japan



# Pioneers in scanned beam delivery



Building Gantry 1 back in the 1990s  
(Photo: Paul Scherrer Institute)



1998  
Pilot project at GSI  
Germany and proposal for HIT facility

# Status of Radiation Therapy Equipment

**20** **106**

Countries

RT Centres

**110**

Light Ion Therapy

## Equipment type

(Updated on : 23/06/2021 09:19:53)

MV Therapy 14,875

Brachytherapy 3,318

Light Ion Therapy 110


## Equipment per income groups

(Updated on : 23/06/2021 09:19:53)

High income (H) 99

Upper middle income (UM) 10


Lower middle income (LM) 1








200



Messi




Multi heavy ions  
(protons +  
carbon ions)



Higuain



proton multi-room



Mandžukić

2



Karius

on single-  
room

Courtesy  
(I'll never thank him enough!)  
Marco Durante (GSI)  
JENAS 2019


<https://indico.ijslab.in2p3.fr/event/5418/timetable/#20191016.detailed>

# Protons: the LINAC way

**1990  
RFQ2  
200 MHz  
0.5 MeV /m  
Weight :1200kg/m  
Ext. diametre : ~45 cm**

**2007  
LINAC4 RFQ  
352 MHz  
1MeV/m  
Weight : 400kg/m  
Ext. diametre : 29 cm**

**2014  
HF RFQ  
750MHz  
2.5MeV/m  
Weight : 100 kg/m  
Ext. diametre : 13 cm**



## Compact High-Frequency Radio Frequency Quadrupole (RFQ)

M. Vretenar, A. Dallochio, V. A. Dimov, M. Garlasché, A. Grudiev, A. M. Lombardi, S. Mathot, E. Montesinos, M. Timmins, "A Compact High-Frequency RFQ for Medical Applications", in Proc. LINAC2014, Geneva, Switzerland, September 2014



Knowledge Transfer  
Accelerating Innovation





Fig. 4. TOP-IMPLART SCDTL structure: (left) schematic (right) 18-24 MeV booster built for the SPARKLE Company.

## TOP IMPLART

C. Ronsivalle, M. Carpanese, C. Marino, G. Messina, L. Picardi, S. Sandri, E. Basile, B. Caccia, D.M. Castelluccio, E. Cisbani, S. Frullani, F. Ghio, V. Macellari, M. Benassi, M. D'Andrea, L. Strigari, The TOP-IMPLART project, Eur. Phys. J. Plus 126: 68 (2011) 1–15, <http://dx.doi.org/10.1140/epjp/i2011-11068-x>.



## LInac BOoster (LIBO)


U. Amaldi et al., "LIBO-a linac booster for protontherapy: construction and test of a prototype," Nucl. Instrum. Meth- ods Phys. Res. A, vol. 521, pp. 512-529, 2004.




# Toward clinical proton therapy LINACs

The RFQ accelerating structure entirely manufactured by AVO (under CERN licence) has completed the Factory Acceptance Testing protocols and is RF tuned.

System being progressively installed at STFC (Daresbury) AVO integration site.



CERN proton therapy RFQ (5 MeV / 2m)



TOP IMPLART under development and construction by ENEA in collaboration with the Italian Institute of Health (ISS) and the Oncological Hospital Regina Elena-IFO.

Status in March 2021\*: running at 55.5 MeV


\*<http://www.frascati.enea.it/accelerators/Sito/TopImplartStatus&Schedules/index.htm>

ERHA (Enhanced Radiotherapy with Hadrons) is the innovative proton therapy system being developed by LinearBeam for the treatment of tumors.



Collaboration with (among others) ENEA, INFN.



# Carbon ions










From pioneering rasterscanning & carbon ion pilot project @




440 patients  
1998-2008



The image shows an optimized plan with two opposite fields for a chordoma patient using protons (left) or  $^{12}\text{C}$  ions (right).

Image from the GSI patient project archive,  
distributed under [Creative Commons CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).



Since 2009\*:  
2841 patients with p  
3793 patients with C-ion

\* Until Dec 2020, source ptcog.ch



## PROTON-ION MEDICAL MACHINE STUDY (PIMMS) PART II

Accelerator Complex Study Group\*  
supported by the Med-AUSTRON, Onkologie-2000 and the TERA Foundation  
and hosted by CERN

### ABSTRACT

The Proton-Ion Medical Machine Study (PIMMS) group was formed following an agreement between the Med-AUSTRON (Austria) and the TERA Foundation (Italy) to combine their efforts in the design of a cancer therapy synchrotron capable of accelerating either light ions or protons. CERN agreed to support and host this study in its PS Division. A close collaboration was also set up with GSI (Germany). The study group was later joined by Onkologie-2000 (Czech Republic). Effort was first focused on the theoretical understanding of slow extraction and the techniques required to produce a smooth beam spill for the conformal treatment of complex-shaped tumours with a sub-millimetre accuracy by active scanning with proton and carbon ion beams. Considerations for passive beam spreading were also included for protons. The study has been written in two parts. The more general and theoretical aspects are recorded in Part I and the specific technical design considerations are presented in the present volume, Part II. An accompanying CD-ROM contains supporting publications made by the team and data files for calculations. The PIMMS team started its work in January 1996 in the PS Division and continued for a period of four years.

\*Full-time members: L. Badano<sup>1)</sup>, M. Benedikt<sup>2)</sup>, P.J. Bryant<sup>2)</sup> (Study Leader), M. Crescenti<sup>1)</sup>, P. Holy<sup>3)</sup>, A. Maier<sup>2)\*4)</sup>, M. Pullia<sup>1)</sup>, S. Reimoser<sup>2)\*4)</sup>, S. Rossi<sup>1)</sup>,  
Part-time members: G. Borri<sup>1)</sup>, P. Knaus<sup>1)\*2)</sup>  
Contributors: F. Gramatica<sup>1)</sup>, M. Pavlovic<sup>5)</sup>, L. Weisser<sup>5)</sup>

1) TERA Foundation, via Puccini. 11, I-28100 Novara.

2) CERN, CH 1211 Geneva-23.


3) Oncology-2000 Foundation, Na Morani 4, CZ-12808 Prague 2.

4) Med-AUSTRON, c/o RIZ, Prof. Dr. Stephan Korenstr.10, A-2700 Wr. Neustadt.


5) Sommer & Partner Architects Berlin (SPB), Hardenbergplatz 2, D-10623 Berlin.

Geneva, Switzerland  
May 2000

From PIMMS @



fondazione CNAO



# Patient treatment at MedAustron



Since 2016:  
1174 Patients  
30600 Single Fractions

MedAustron 



<b>CNS</b>	<b>28%</b>
<b>Head &amp; Neck</b>	<b>20%</b>
<b>Pediatrics</b>	<b>15%</b>
<b>Re-Irradiation</b>	<b>15%</b>
<b>Sarcoma</b>	<b>9%</b>
<b>Skull Base</b>	<b>7%</b>
<b>Prostate</b>	<b>3%</b>
<b>Gastrointestinal (upper)</b>	<b>2%</b>
<b>Gastrointestinal (lower)</b>	<b>&lt;1%</b>
<b>Gynecological Tumors</b>	<b>&lt;1%</b>
<b>Urogenital Tumors</b>	<b>&lt;1%</b>
<b>Breast/Mamma-Ca</b>	<b>&lt;1%</b>

Values October 2021 • values rounded



# Patient treatment at CNAO

Since 2011:  
3700 Patients  
55% C-ions  
45% Protons



Non oncological application: ventricular arrhythmia  
(Collaboration with San Matteo Hospital, Pavia)  
Published: European Journal of Heart Failure

# SCIENTIFIC REPORTS

OPEN

## Feasibility Study on Cardiac Arrhythmia Ablation Using High-Energy Heavy Ion Beams

Received: 08 August 2016  
Accepted: 09 November 2016  
Published: 20 December 2016

H. Immo Lehmann<sup>1,4</sup>, Christian Graeff<sup>2,4</sup>, Palma Simoniello<sup>2</sup>, Anna Constantinescu<sup>2</sup>, Mitsuru Takami<sup>1</sup>, Patrick Lugenbiel<sup>3</sup>, Daniel Richter<sup>2,4</sup>, Anna Eichhorn<sup>2</sup>, Matthias Prall<sup>2</sup>, Robert Kaderka<sup>2</sup>, Fine Fiedler<sup>5</sup>, Stephan Helmbrecht<sup>5</sup>, Claudia Fournier<sup>2</sup>, Nadine Erbeltinger<sup>2</sup>, Ann-Kathrin Rahm<sup>3</sup>, Rasmus Rivinius<sup>3</sup>, Dierk Thomas<sup>3</sup>, Hugo A. Katus<sup>3</sup>, Susan B. Johnson<sup>2</sup>, Kay D. Parker<sup>2</sup>, Jürgen Debus<sup>6</sup>, Samuel J. Asirvatham<sup>1</sup>, Christoph Bert<sup>2,4</sup>, Marco Durante<sup>2,7</sup> & Douglas L. Packer<sup>1</sup>

> Eur J Heart Fail. 2020 Nov 12. doi: 10.1002/ejhf.2056. Online ahead of print.

## The First-in-Man Case of Non-invasive Proton Radiotherapy to Treat Refractory Ventricular Tachycardia in Advanced Heart Failure

Veronica Dusi<sup>1,2</sup>, Viviana Vitolo<sup>3</sup>, Laura Frigerio<sup>1,4</sup>, Rossana Totaro<sup>1,4</sup>, Adele Valentini<sup>5</sup>, Amelia Barcellini<sup>3</sup>, Alfredo Mirandola<sup>3</sup>, Giovanni Battista Perego<sup>6</sup>, Michela Coccia<sup>2</sup>, Alessandra Greco<sup>4</sup>, Stefano Ghio<sup>4</sup>, Francesca Valvo<sup>3</sup>, Gaetano Maria De Ferrari<sup>7</sup>, Massimiliano Gnechi<sup>1,2</sup>, Luigi Oltrona Visconti<sup>4</sup>, Roberto Rordorf<sup>1,4</sup>

Affiliations + expand

PMID: 33179329 DOI: 10.1002/ejhf.2056





# Challenges for next-generation particle-therapy machines

Cost-effective technologies

Reduced footprint

New treatment regimes (e.g. FLASH, microbeams) and fractionation schedules

Multi-ions

Radiobiology research integrated in the facility

Many challenges in common with those for future particle physics facilities. Various initiatives starting/on-going.

KT Seminars

## The CERN Next Ion Medical Machine Study: towards a new generation of accelerators for cancer therapy

by Maurizio Vretenar (CERN)

Monday 19 Oct 2020, 14:00 → 16:30 Europe/Z

<https://indico.cern.ch/event/956260/>

**Workshop**  
Location Archamps, France  
Venue: European Scientific Institute (ESI)  
Dates: 19-21 June 2018

### Ideas and technologies for a next-generation facility for medical research and therapy with ions



**MAIN TOPICS:**

- ▶ EXISTING FACILITIES
- ▶ CURRENT INITIATIVES
- ▶ NEW TECHNOLOGIES
- ▶ DESIGN PARAMETERS
- ▶ TECHNICAL OPTIONS

<https://indico.cern.ch/e/ions2018>

ORGANIZATION	International Advisory Committee	Programme Committee	Organizing Committee
	U. Amaldi (TIFR, Italy) F. Bordry (CERN, Switzerland) J. Debus (HIT, Germany) M. Durante (TIFR, INFN, Italy) P. Giubellino (GSI & FAIR, Germany) R. Miralbell (HUG, Switzerland) S. Rossi (CNAO, Italy) H. Specht (Univ. of Heidelberg, Germany) E. Tsesmelis (CERN, Switzerland) U. Weinrich (GSI & FAIR, Germany) A. Zent (MedAustron, Austria)	M. Cirilli (CERN, Switzerland) M. Dosanjh (CERN/ENLIGHT, Switzerland) Y. Foka (GSI & FAIR, Germany) C. Geiffert (GSI & FAIR, Germany) M. Pullia (CNAO, Italy) L. Rindolf (ESI, France) M. Vretenar (CERN, Switzerland)	V. Branner (CERN, Switzerland) Y. Foka (GSI & FAIR, Germany) B. Holland (ESI, France) M. Janik (IMP, Poland) A. Katanevskiy (JINR, Dubna & SPbSU, Russia) L. Rindolf (ESI, France) M. Vretenar (CERN, Switzerland)


      



# Three alternative accelerator designs


## Improved synchrotron (warm)

Equipped with several innovative features: multi-turn injection for higher beam intensity, new injector at higher gradient and energy, multiple extraction schemes, multi-ion. Circumference  $\sim 75$  m




## Improved synchrotron (superconducting)

Equipped with the same innovative features as warm, but additionally  $90^\circ$  superconducting magnets. Circumference  $\sim 27$  m





Courtesy: TERA






## Linear accelerator

Linear sequence of accelerating cells, high pulse frequency. Length  $\sim 53$  m




Other options considered as less interesting because of cost and/or required R&D: RC synchrotron, FFAG, SC cyclotron, PWFA

# The RFQ for C<sup>6+</sup> LINAC option



First (of 4 sections) completed





Collaboration CERN-CIEMAT-CDTI-Spanish industry  
2.0 m long  
750 MHz  
Will deliver Carbon (or Helium) at 5 MeV (total energy)  
Designed at CERN built in Spanish Industry




# R&D on gantries


GaToroid: A Novel Concept for a Superconducting Compact and Lightweight Gantry for Hadron Therapy



Collaboration CNAO-INFN-CERN-MedAustron  
start 2022



**SIGRUM**  
Superconducting Ion  
Gantry with Riboni's  
Unconventional Mechanics



## CSN5 – Call 2021

### SIG

## Superconducting Ion Gantry

Lucio Rossi

Università di Milano e sezione INFN di Milano – LASA

R. Musenich INFN-GE, L. Sabbatini INFN, S. Giordanengo e E. Fiorina INFN-TO

# Protons stop...but where?



(Range uncertainty)

Courtesy Marco Durante



# Range monitoring

# Dosimetry

# Moving organs

# Clinical Trials


## Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments

Alexander Helm; Daniel K. Ebner; Walter Tinganelli; Palma Simoniello; Alessandra Bisio; Valentina Marchesano; Marco Durante; Shigeru Yamada; Takashi Shimokawa

*Int J Part Ther* (2018) 5 (1): 84–93.

<https://doi.org/10.14338/IJPT-18-00024.1>

## Impact of proton therapy on antitumor immune response



[Céline Mirjolet](#) , [Anaïs Nicol](#), [Emeric Limagne](#), [Carole Mura](#), [Corentin Richard](#), [Véronique Morgand](#), [Marc Rousseau](#), [Romain Boidot](#), [François Ghiringhelli](#), [Georges Noel](#) & [Hélène Burckel](#)

*Scientific Reports* **11**, Article number: 13444 (2021) | [Cite this article](#)

# Look even further





## Laser-hybrid Accelerator for Radiobiological Applications



Credit: LhARA Consortium

## Quantum Scalpel



5th generation facility:

Superconducting synchrotron

Multi-ion irradiation system

Injector with laser acceleration technology

Rotating gantry with HTS magnets

Microsurgery system



# FLASH therapy – a growing clinical interest

NATURE

May 23, 1959 VOL. 183

## Modification of the Oxygen Effect when Bacteria are given Large Pulses of Radiation

D. L. DEWEY  
J. W. BOAG

Research Unit in Radiobiology,  
British Empire Cancer Campaign,  
Mount Vernon Hospital,  
Northwood.

> [Sci Transl Med](#). 2014 Jul 16;6(245):245ra93. doi: 10.1126/scitranslmed.3008973.

## Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice

Vincent Favaudon<sup>1</sup>, Laura Caplier<sup>2</sup>, Virginie Monceau<sup>3</sup>, Frédéric Pouzoulet<sup>4</sup>,  
Mano Sayarath<sup>4</sup>, Charles Fouillade<sup>4</sup>, Marie-France Poupon<sup>4</sup>, Isabel Brito<sup>5</sup>, Philippe Hupé<sup>6</sup>,  
Jean Bourhis<sup>7</sup>, Janet Hall<sup>4</sup>, Jean-Jacques Fontaine<sup>2</sup>, Marie-Catherine Vozenin<sup>8</sup>

Affiliations + expand

PMID: 25031268 DOI: [10.1126/scitranslmed.3008973](#)

In vitro studies suggested that sub-millisecond pulses of radiation elicit less genomic instability than continuous, protracted irradiation at the same total dose. To determine the potential of ultrahigh dose-rate irradiation in radiotherapy, we investigated lung fibrogenesis in C57BL/6J mice exposed either to short pulses ( $\leq 500$  ms) of radiation delivered at ultrahigh dose rate ( $\geq 40$  Gy/s, FLASH) or to conventional dose-rate irradiation ( $\leq 0.03$  Gy/s, CONV) in single doses. The growth of human HBCx-12A and HEP-2 tumor xenografts in nude mice and syngeneic TC-1 Luc(+) orthotopic lung tumors in C57BL/6J mice was monitored under similar radiation conditions. CONV (15 Gy) triggered lung fibrosis associated with activation of the TGF- $\beta$  (transforming growth factor- $\beta$ ) cascade, whereas no complications developed after doses of FLASH below 20 Gy for more than 36 weeks after irradiation. FLASH irradiation also spared normal smooth muscle and epithelial cells from acute radiation-induced apoptosis, which could be reinduced by administration of systemic TNF- $\alpha$  (tumor necrosis factor- $\alpha$ ) before irradiation. In contrast, FLASH was as efficient as CONV in the repression of tumor growth. Together, these results suggest that FLASH radiotherapy might allow complete eradication of lung tumors and reduce the occurrence and severity of early and late complications affecting normal tissue.

# FLASH therapy – a growing clinical interest



Vozenin et al  
*Clin Cancer Res*  
2018



Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: [www.thegreenjournal.com](http://www.thegreenjournal.com)



Original Article

## Treatment of a first patient with FLASH-radiotherapy

Jean Bourhis<sup>a,b,\*</sup>, Wendy Jeanneret Sozzi<sup>a</sup>, Patrik Gonçalves Jorge<sup>a,b,c</sup>, Olivier Gaide<sup>d</sup>, Claude Bailat<sup>c</sup>, Frédéric Duclos<sup>a</sup>, David Patin<sup>a</sup>, Mahmut Ozsahin<sup>a</sup>, François Bochud<sup>c</sup>, Jean-François Germond<sup>c</sup>, Raphaël Moeckli<sup>c,1</sup>, Marie-Catherine Vozenin<sup>a,b,1</sup>


<sup>a</sup>Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; <sup>b</sup>Radiation Oncology Laboratory, Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne; <sup>c</sup>Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne; and <sup>d</sup>Department of Dermatology, Lausanne University Hospital and University of Lausanne, Switzerland




Fig. 1. Temporal evolution of the treated lesion: (a) before treatment; the limits of the PTV are delineated in black; (b) at 3 weeks, at the peak of skin reactions (grade 1 epithelitis NCI-CTCAE v 5.0); (c) at 5 months.

First human patient – skin cancer  
treated with 10 MeV-range electrons






(a)



(b)

<https://www.mdpi.com/2072-6694/13/19/4942/htm>



TOPAS-based Monte Carlo simulations of the integrated normalised dose deposited in the plane parallel to the direction of an incident Gaussian beam ( $\sigma=4\text{mm}$ ). All beams are in the absence of focusing

<https://www.nature.com/articles/s41598-021-93276-8#Fig1>





# VHEE'17

Very High Energy Electron  
Radiotherapy: Medical &  
Accelerator Physics Aspects  
Towards Machine Realisation

JULY 24 – 26, 2017  
COCKCROFT INSTITUTE

## Scientific Programme Committee:

Roger M. Jones	University of Manchester/Cockcroft Institute, UK – Chair
Colleen DesRosiers	Indiana University, USA
Angeles Faus-Golfe	IFIC, Spain, and CNRS/LAL, France
Dino Jaroszynski	University of Strathclyde, UK
Karen Kirkby	University of Manchester, UK
Ronald Mackay	The Christie, UK
Peter McIntosh	STFC Daresbury Laboratory, UK
Hywel Owen	University of Manchester/Cockcroft Institute, UK
Jiaru Shi	Tsinghua University, China
Sami Tantawi	SLAC National Accelerator Lab, USA
Marcel Van Herk	The Christie/Manchester University, UK
Alan Wheelhouse	STFC Daresbury Laboratory, UK

## Local Organizing Committee:

Deepa Angal-Kalinin	STFC Daresbury Laboratory – Chair
Roger M. Jones	University of Manchester/ Cockcroft Institute
Nirav Joshi	University of Manchester/ Cockcroft Institute
Peter McIntosh	STFC Daresbury Laboratory
Hywel Owen	University of Manchester/ Cockcroft Institute
Sue Waller	STFC Daresbury Laboratory



This workshop will explore fundamental issues associated with the development of a radiotherapy machine capable of delivering 250 MeV electrons at a high dose. We will explore both the dose delivery aspects, and the potential to realise a radiotherapy machine suitable for patient treatment.


[www.cockcroft.ac.uk/events/VHEE17](http://www.cockcroft.ac.uk/events/VHEE17)





# The CERN Linear Electron Accelerator for Research (CLEAR)

CLEAR is a versatile 200 MeV electron linac + a 20m experimental beamline, operated at CERN as a multi-purpose user facility.






# VHEE activities in CLEAR

Calibration of operational medical dosimeters  
– nonlinear effects with high-dose short pulses


Verification of FLASH effect using biological dosimeters

Experimental verification of dose deposition profiles in water phantoms


Demonstration of “Bragg-like peak” deposition with focused beams



Strathclyde  
and Manchester



Films set-up for profile depth dose, CHUV Lausanne  
(M.C. Vozenin, C. Bailat, R. Moeckli et al.)



Calorimeter and ROOS chamber, Nat. Phys. Lab. UK  
(A. Subiel et al.)



Advance Markus chambers and SRS Array,  
Oldenburg University and PTW  
(B. Poppe, D. Poppinga et al.)

A. Lagdza, R. Jones et al., Influence of heterogeneous media on Very High Energy Electron (VHEE) dose penetration and a Monte Carlo-based comparison with existing radiotherapy modalities, Nuclear Inst. and Meth. in Physics Research, B, 482 (2020) 70-81.

M. McManus, A. Subiel et al., The challenge of ionisation chamber dosimetry in ultra-short pulsed high dose-rate Very High Energy Electron beams, Nature Scientific Reports (2020) 10-9089.

Small, K.L., Henthorn, et al., Evaluating very high energy electron RBE from nanodosimetric pBR322 plasmid DNA damage, Nature Sci. Rep. 11, 3341 (2021).

D. Poppinga et al., VHEE beam dosimetry at CERN Linear Electron Accelerator for Research under ultra-high dose rate conditions, 2021 Biomed. Phys. Eng. Express 7 015012.

Kokurewicz, K., Brunetti, E., Curcio, A. et al. An experimental study of focused very high energy electron beams for radiotherapy, Nature Commun. Phys. 4, 33 (2021).

**Table 1.** Main parameters for the VHEE sources cited in this document.

Beam Parameters	CLEAR	SPARC	NLCTA
Energy (MeV)	50–220	170	50–120
Bunch charge (pC/shot)	150	60	30
Bunch length rms (ps)	0.1–10	0.87	1
Repetition rate (Hz)	0.8–10	0.1–10	0.1–10
Beam size at water phantom surface ( $\sigma$ mm)	1.2	3.4	2

**Table 2.** List of facilities or accelerators under development for VHEE production.

Beam Parameters	PHASER	CLARA	PITZ	Argonne	Tsinghua University
Energy (MeV)	100–200	50 (–250)	20 (–250)	6–63	45 (–350)
Bunch charge (pC/shot)	-	20–100	0.1–5000	100–10 <sup>5</sup>	200
Bunch length rms (ps)	3.10 <sup>5</sup>	0.3–5	30	0.3	<2
Repetition rate (Hz)	10	10 (–100)	10	0.5–10	5–50


<https://www.mdpi.com/2072-6694/13/19/4942/htm>




# CERN – CHUV collaboration on FLASH VHEE therapy



CLIC technology for a FLASH VHEE facility being designed in collaboration with CHUV



Close-up of the Compact Linear Collider prototype, on which the electron FLASH design is based (Image: CERN)



An intense beam of electrons is produced in a photoinjector, accelerated to around 100 MeV and then is expanded, shaped and guided to the patient.

The design of this facility is the result of an intense dialogue between groups at CHUV and CERN.

Jean Bourhis from CHUV:

“The clinical need that we have really converges with the technological answer that CERN has.”



# The remarkable connection between CLIC technology and FLASH electron therapy



## Very intense electron beams

CLIC – to provide brightness needed for delicate physics experiments

FLASH – to provide dose fast for biological FLASH effect

## Very precisely controlled electron beams

CLIC – to reduce the power consumption of the facility

FLASH – to provide reliable treatment in a clinical setting

## High accelerating gradient (that is high beam energy gain per length)

CLIC – fit facility in Lac Lemman region and limit cost


FLASH – fit facility on typical hospital campuses and limit cost of treatment



CERN KT Seminar on April 26<sup>th</sup>, 2021  
<https://indico.cern.ch/event/975980/>



# X RAYS



# Georges Charpak's MWPC

EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH

File: *Charpak chambers*

THE USE OF MULTIWIRE PROPORTIONAL COUNTERS  
TO SELECT AND LOCALIZE CHARGED PARTICLES

G. Charpak, R. Bouclier, T. Bressani, J. Favier  
and Č. Zupančič

CERN, Geneva, Switzerland.

## ABSTRACT


Properties of chambers made of planes of independent wires placed between two plane electrodes have been investigated. A direct voltage is applied to the wires. It has been checked that each wire works as an independent proportional counter down to separation of 0.1 cm between wires.

- Counting rates of  $10^5$ /wire are easily reached.
- Time resolutions of the order of 100 nsec have been obtained in some gases.
- It is possible to measure the position of the tracks between the wires using the time delay of the pulses.
- Energy resolution comparable to the one obtained with the best cylindrical chambers is observed.
- The chambers can be operated in strong magnetic fields.

Geneva - 23 February, 1968

(Submitted to Nucl. Instrum. and Methods)

SIS/kw/sb





First mouse imaged at CERN with Na-<sup>18</sup>F in 1978

SCAN OF MOUSE SKELETON.  $5.7 \mu\text{Ci}$ ,  $\text{F}^{18}$  (positron emission)  
1 bin  $\equiv 1\text{mm} \times 1\text{mm}$ . Plane spacing =  $1\text{cm}$ .

## RECONSTRUCTION

[illegible][illegible]

+ 8.0 cm.


[illegible][illegible]

+ 9.0 cm.

[illegible][illegible] $+10.0 \text{ cm}$ [illegible][illegible]



# David Townsend, Alan Jeavons



Phys. Med. Biol., 1983, Vol. 28, No. 9, 1009–1019. Printed in Great Britain

## A general method for three-dimensional filter computation


B Schorr<sup>†</sup>, D Townsend<sup>‡</sup> and R Clack<sup>‡</sup>

<sup>†</sup> DD Division, CERN, Geneva, Switzerland

<sup>‡</sup> Department of Nuclear Medicine, Cantonal Hospital, Geneva, Switzerland


Received 24 September 1982, in final form 7 February 1983

**Abstract.** Application of the Fourier space deconvolution algorithm to three-dimensional (3D) reconstruction problems necessitates the computation of a frequency space filter; which requires taking the 3D Fourier transform of the system response function. In this paper, it is shown that for system response functions of the specific form  $d(\theta, \varphi)/r^2$ , with  $d(\theta, \varphi)$  an angular function describing the imaging system, the filter computation can always be reduced to a single integration which, in many cases, may be performed analytically. Complete expressions are derived for the general 3D filter, and two examples are given to illustrate the use of such expressions.






# Projectional radiography



[https://en.wikipedia.org/wiki/X-ray\\_detector#/media/File:Projectional\\_radiography\\_components.jpg](https://en.wikipedia.org/wiki/X-ray_detector#/media/File:Projectional_radiography_components.jpg)  
Blausen Medical Annotations by Mikael Hågström - By Blaussen Medical.  
<https://creativecommons.org/licenses/by-sa/4.0/>

# Fast forward to 2018




First 3D colour X-ray of human extremities using the Medipix3 technology developed at CERN




# Medipix

A family of pixel detector read-out chips for particle imaging and detection developed by the Medipix Collaborations

A photograph of a Medipix1 chip, which is a long, narrow integrated circuit with a dense array of gold pins along one edge, mounted on a dark printed circuit board.


## › Medipix1 Collaboration

The Medipix1 collaboration was formed in the 1990's when the potential of the new technology to provide noise-free single-photon counting was demonstrated.

A photograph of a Medipix2 probe card, showing a square chip mounted on a green circuit board with various electronic components like capacitors and resistors.


## › Medipix2 Collaboration

The Medipix2 Collaboration was formed in 1999 with the aim of developing a single photon counting pixel detector readout chip using a  $0.25\ \mu\text{m}$  CMOS process.

A photograph of a Medipix3 chip, a square integrated circuit with a gold-colored border, mounted on a dark circuit board.

## › Medipix3 Collaboration




The Medipix3 Collaboration was formed in 2005 to develop the Medipix3 chip and the Timepix3 chip: now permitting colour imaging and dead time free operation.

A photograph of two Medipix4 chips, one purple and one red, mounted on circuit boards. They are square chips with complex internal patterns and gold pins.

## › Medipix4 Collaboration

The Medipix4 Collaboration was launched in 2017. The aim is designing pixel read-out chips fully prepared for TSV processing that may be tiled on all four sides.




# Hybrid Silicon Pixel Detectors



Noise-hit free particle detection  
Standard CMOS can be used allowing on-pixel signal processing  
Sensor material can be changed (Si, GaAs, CdTe..)




# Hybrid Silicon Pixel Detectors: counting electronics




Open shutter

Close shutter



→ Noise hit free imaging

# Colour x-ray of a lighter




S. Procz et al.



# Spectral imaging of Joints


Titanium implant in sheep bone



Enables better understanding of

- process of bone ingrowth
- bone / implant interface

# Spectroscopic information permits material separation




The water has been partly cut away to reveal the  
bone, gold, gadolinium and iodine



Images presented at the European Congress of Radiology, Vienna, March 2017.



# Spectral CT image showing wrist implant



# Hafnia accumulation at bone microcracks



Molecular imaging using metal nanoparticles - spectral CT



Colour 3D X-ray  
image of a fatty  
deposit on an artery  
(carotid plaque)  
taken using a  
Medipix3 detector

Image by Mars Bio-Imaging

Feature article link:

<https://rdcu.be/bOFuR>






Ethanol-preserved mouse heart scanned using the WidePIX<sub>10x5</sub> detector  
60 kVp tungsten spectrum  
720 projections, 5 seconds per projection (one hours total)  
Spatial resolution ca. 7  $\mu$ m  
Reconstructed using Voxel, visualized using CTvox and Amide software




# MiniPIX TPX3

## Miniaturized spectral camera supporting Si and CdTe sensors








**ADVACAM**  
Imaging the Unseen

It's really small...




# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources






# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

100 – 150 keV



# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources


150 – 200 keV







# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

200 – 250 keV



# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources



250 – 300 keV







# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

300 – 350 keV



# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources


350 – 400 keV







# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

400 – 450 keV



# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources



450 – 500 keV






# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

500 – 550 keV





# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

550 – 600 keV



# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources



600 – 650 keV






# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

650 – 700 keV




# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

700 – 750 keV




# Single Layer Compton Camera with MiniPIX TPX3 – Multiple Gamma Sources

250 – 300 keV




$^{131}\text{I}$  284 keV (7%)

350 – 400 keV




$^{131}\text{I}$  364 keV

500 – 550 keV




$^{22}\text{Na}$  511 keV

650 – 700 keV



$^{137}\text{Cs}$  662 keV





# Gamma camera applications: Thyroid diagnostic

Thyroid cancer diagnostics and treatment monitoring:


The second most frequent cancer for women (after breast cancer)

Current imaging methods offer resolution of about 12 mm in 2D

This technology allows


5 times better resolution and 3D (2.5 mm)

4 times lower dose




# In-line images of a hadron therapy beam

Protons 48 MeV




Only protons and their scattering, no secondaries.

Protons 221 MeV




Many secondaries, (delta electrons fragments).

Carbons 89 MeV/u



Carbons and protons and their scattering, no secondaries.

Carbons 430 MeV/u



Carbons and many secondaries.



Timepix chip combined with Si detector

# Timepix on the ISS






# GEMPix for QA in Hadron Therapy



Water phantom donated from Luzern hospital equipped with GEMPix, reference PTW ion chamber + readout

Ion chamber, GEMPix and movement in water phantom integrated in one system (HW/SW)

Measurements at CNAO – Italian National Centre for Oncological Hadron therapy





J. Leidner, M. Ciocca, S. P. George, A. Mirandola, F. Murtas, A. Rimoldi, M. Silari and A. Tamborini. 3D Energy deposition measurements with the GEMPix detector in a water phantom for hadron therapy. *Journal of Instrumentation* 13, P08009 (2018)

J. Leidner, M. Ciocca, A. Mairani, F. Murtas and M. Silari. A GEMPix-based integrated system for measurements of 3D dose distributions in water for carbon ion scanning beam radiotherapy. *Medical Physics* 47, 2516-2525 (2020)

# GEMPix: measurements with a $^{12}\text{C}$ beam at CNAO

2D images with much better spatial resolution than with an ion chamber





# TimePIX 3 photon fluence measurement in hospital theatres




Reference person: 1.76 m

Eye lens - 170 cm

Chest - 135 cm

Belt - 96 cm

Knee - 53 cm





Colour maps of the photon fluence measured with a Timepix III in an hospital theatre at four horizontal heights.

Courtesy of M. Nowak



# TimePIX 3 photon fluence measurement in hospital theatres

Energy spectra for each height for a given person




Courtesy of M. Nowak




Shift in energy from head to toes = non homogenous exposure

# PET



# Positron Emission Tomography


















## ClearPET


PET for small animals



## ClearPET

Dedicated scanner for breast imaging






# Current status commercial TOF-PET



## TOF PET SIEMENS: BIOGRAPH VISION



3.2mm section crystals  
CTR 215ps





Webpage SIEMENS:

[https://static.healthcare.siemens.com/siemens\\_hwem-hwem\\_sxxa\\_websites-context-root/wcm/idc/groups/public/@global/@imaging/@molecular/documents/download/mda4/mzmy/~edisp/biograph\\_vision\\_technical\\_flyer-05440720.pdf](https://static.healthcare.siemens.com/siemens_hwem-hwem_sxxa_websites-context-root/wcm/idc/groups/public/@global/@imaging/@molecular/documents/download/mda4/mzmy/~edisp/biograph_vision_technical_flyer-05440720.pdf)

[See presentation KT/EP seminar 6 September 2021 from Maurizio Conti](#)



# In the CERN Crystal Clear group: <160 ps with DOI





Type of array	Crystals dim. [mm <sup>3</sup> ]	DOI resolution FWHM [mm]	En. Res. FWHM @ 511 keV [%]	CTR FWHM [ps], central pixels	
				<i>No correction</i>	<i>With DOI correction</i>
DOI	3.1 x 3.1 x 15	3.0 ± 0.1	8.9 ± 0.2	234 ± 2	157 ± 2

DOI information extracted without degradation of timing properties

*M. Pizzichemi et al, Phys. Med. Biol. 61 (2016) 4679*

## ■ PET DETECTOR





[J Med Imaging \(Bellingham\)](#), 2017 Jan; 4(1): 011005.  
Published online 2016 Dec 2. doi: [10.1117/1.JMI.4.1.011005](#)

PMCID: PMC5133454  
PMID: [27981069](#)

### INSIDE in-beam positron emission tomography system for particle range monitoring in hadrontherapy

[Maria Giuseppina Bisogni](#),<sup>a,b,\*</sup> [Andrea Attili](#),<sup>c,d</sup> [Giuseppe Battistoni](#),<sup>e</sup> [Nicola Belcarì](#),<sup>a,b</sup> [Niccolò Camarlinghi](#),<sup>a,b</sup> [Piergiorgio Cerello](#),<sup>d</sup> [Silvia Coli](#),<sup>d</sup> [Alberto Del Guerra](#),<sup>a,b</sup> [Alfredo Ferrari](#),<sup>f</sup> [Veronica Ferrero](#),<sup>c,d</sup> [Elisa Fiorina](#),<sup>d</sup> [Giuseppe Giraudo](#),<sup>d</sup> [Eleftheria Kostara](#),<sup>b</sup> [Matteo Morrocchi](#),<sup>a,b</sup> [Francesco Pennazio](#),<sup>d</sup> [Cristiana Peroni](#),<sup>c,d</sup> [Maria Antonietta Piliero](#),<sup>a,b</sup> [Giovanni Pirrone](#),<sup>a,b</sup> [Angelo Rivetti](#),<sup>d</sup> [Manuel D. Rolo](#),<sup>d</sup> [Valeria Rosso](#),<sup>a,b</sup> [Paola Sala](#),<sup>e</sup> [Giancarlo Sportelli](#),<sup>a,b</sup> and [Richard Wheadon](#)<sup>d</sup>



# Radioisotopes



## Radioisotopes: The medical testing crisis

With a serious shortage of medical isotopes looming, innovative companies are exploring ways to make them without nuclear reactors.

Richard Van Noorden

11 December 2013

[PDF](#) [Rights & Permissions](#)



# Radioisotopes & Nuclear Medicine


## Classification of isotopes for Medicine:

1. Established isotopes → Industrial suppliers  
 $^{99m}\text{Tc}$ ,  $^{18}\text{F}$ ,  $^{123,125,131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{90}\text{Y}$
2. Emerging isotopes → Small innovative suppliers  
 $^{68}\text{Ga}$ ,  $^{82}\text{Rb}$ ,  $^{89}\text{Zr}$ ,  $^{177}\text{Lu}$ ,  $^{188}\text{Re}$
3. R&D isotopes → Research labs  
 $^{44,47}\text{Sc}$ ,  $^{64,67}\text{Cu}$ ,  $^{134}\text{Ce}$ ,  $^{140}\text{Nd}$ ,  $^{149, 152, 155, 161}\text{Tb}$ ,  $^{166}\text{Ho}$ ,  $^{195\text{m}}\text{Pt}$ ,  $^{211}\text{At}$ ,  $^{212}$ ,  $^{213}\text{Bi}$ ,  $^{223}\text{Ra}$ ,  $^{225}\text{Ac}$ , ...



Courtesy U. Koester





68Ga-PSMA-11 PET/CT scans of patient B. In comparison to initial tumor spread (A), restaging after 2 cycles of  $\beta$ -emitting  $^{177}\text{Lu}$ -PSMA-617 presented progression (B).  
Clemens Kratochwil et al. J Nucl Med 2016;57:1941-1944



# Theranostics

<div><div>Tb 149</div><div><div>4.2 m</div><div>4.1 h</div></div><div><div>ε</div><div>β<sup>+</sup></div><div>α 3.99</div><div>γ 796;</div><div>165...</div></div><div><div>ε</div><div>α 3.97</div><div>β<sup>+</sup> 1.8</div><div>γ 352;</div><div>165...</div></div></div>	<div><div>Tb 152</div><div><div>4.2 m</div><div>17.5 h</div></div><div><div>ly 283;</div><div>160...</div><div>ε; β<sup>+</sup>...</div><div>γ 344;</div><div>411...</div></div><div><div>ε</div><div>β<sup>+</sup> 2.8...</div><div>γ 344;</div><div>586;</div><div>271...</div></div></div>
<div><div>Tb 155</div><div>5.32 d</div><div><div>ε</div><div>γ 87;</div><div>105;...</div><div>180, 262</div></div></div>	<div><div>Tb 161</div><div>6.90 d</div><div><div>β<sup>-</sup> 0.5; 0.6...</div><div>γ 26; 49; 75...</div><div>e<sup>-</sup></div></div></div>





A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

Cristina Müller, Konstantin Zhernosekov, Ulli Köster, Karl Johnston, Holger Dorrer, Alexander Hohn, Nico T. van der Walt, Andreas Türlér and Roger Schibli


Journal of Nuclear Medicine December 2012, 53 (12) 1951-1959; DOI: <https://doi.org/10.2967/jnumed.112.107540>

# ISOLDE has been running @CERN for > 50 years






Non-conventional isotopes collected by mass separation for new medical applications






# Principle of isotope production


## CERN protons




## MEDICIS Laboratory



## Rail Conveyor System



## MEDICIS Target Irradiation



# SPES-Selective Production of Exotic (nuclear) Species @ LNL



## SPES- $\alpha$

production and delivery to the target of Cyclotron proton beams)

## SPES- $\beta$

ISOL facility and the acceleration of neutron-rich unstable nuclei

## SPES- $\gamma$

Radioisotopes for medical applications



## SPES- $\delta$

Neutron source for applied physics and industry

Manuela Cirilli - INFN Student Lecturer, July 2022




# SPES- $\gamma$ : innovative radioisotopes for medical applications

Production of  
radioisotopes for  
medical  
applications via

ISOL technique  
*SPES exotic beams for medicine*

Focused on the use of the ISOL system  
to produce radioisotopes for medicine at  
high specific activity and purity.

INFN patent «Method for producing beta  
emitting radiopharmaceuticals and beta  
emitting radiopharmaceuticals thus  
obtained»



Production of radioisotopes for  
medical  
applications  
via **direct**



Laboratory of Radionuclides for MEDicine

 molecules



Letter

**LARAMED: A Laboratory for Radioisotopes of  
Medical Interest**

Juan Esposito <sup>1</sup>, Diego Bettoni <sup>1,2</sup>, Alessandra Boschi <sup>3</sup>, Michele Calderolla <sup>1</sup>,  
Sara Cisternino <sup>1</sup>, Giovanni Fiorentini <sup>2</sup>, Giorgio Keppel <sup>1</sup>, Petra Martini <sup>1,3,\*</sup>,  
Mario Maggiore <sup>1</sup>, Liliana Mou <sup>1</sup>, Micòl Pasquali <sup>1</sup>, Lorenzo Pranovi <sup>1</sup>, Gaia Pupillo <sup>1</sup>,  
Carlos Rossi Alvarez <sup>1</sup>, Lucia Sarchiapone <sup>1</sup>, Gabriele Sciacca <sup>1</sup>, Hanna Skliarova <sup>1</sup>,  
Paolo Favaron <sup>1</sup>, Augusto Lombardi <sup>1</sup>, Piergiorgio Antonini <sup>1</sup> and Adriano Duatti <sup>1,4</sup>

Manuela Cirilli, Summer Student Lecture, July 2022

[\*] Esposito J et al., Molecules **2019**, 24, 20; doi:10.3390/molecules24010020



# Gamma-MRI project

Development of a new medical diagnostic modality

Combine high spatial resolution (MRI) and high sensitivity (radiotracer)

Proof-of-principle by U Virginia: Y. Zheng, et al., Nature 537, 652 (2016)

Polarised gamma-emitting tracer => anisotropic decay

	Detection efficiency	Spatial resolution
PET and SPECT	high	Low (e.g. >5mm for 82Rb)
MRI	low	High

# Digital Technologies

```
elif operation == "MIRROR_Y":
    mirror_mod.use_x = False
    mirror_mod.use_y = True
    mirror_mod.use_z = False
elif operation == "MIRROR_Z":
    mirror_mod.use_x = False
    mirror_mod.use_y = False
    mirror_mod.use_z = True

#selection at the end -add back the deselected mirror modifier object
mirror_ob.select= 1
modifier_ob.select=1
bpy.context.scene.objects.active = modifier_ob
print("Selected" + str(modifier_ob)) # modifier ob is the active ob
#mirror_ob.select = 0
#name = bpy.context.selected_objects[0]
#bpy.data.objects[name.name].select = 1
print("Please select the mirror modifier to be active")
```

# Geant4 – a simulation toolkit

Open source

CERN strongly contributes to its core development

Other Geant4 collaboration members developed specific capabilities and applied them in G4 medical applications

## Medical Applications

[G4DNA](#)

Geant4–DNA project

[G4MED](#) (in Japanese)

Geant4 Medical Physics in Japan

[G4NAMU](#)

Geant4 North American Medical User Organization

[GAMOS](#)

Geant4–based Architecture for Medicine–Oriented Simulations

[GATE](#)


Geant4 Application for Tomographic Emission

[GHOST](#)

Geant4 Human Oncology Simulation Tool

[TOPAS](#)

Geant4 Monte Carlo Platform for Medical Applications



## GEANT4 collaboration

A SIMULATION TOOLKIT

<http://geant4.cern.ch/>

**Geant4: a simulation toolkit**  
S. Agostinelli *et al.*  
NIM A, vol. 506, no. 3, pp. 250-303, 2003

**Geant4 Developments and Applications**  
J. Allison *et al.*  
IEEE Trans. Nucl. Sci., vol. 53, no. 1, pp. 270-278, 2006

**Recent Developments in Geant4**  
J. Allison *et al.*  
NIM A, vol. 835, pp. 186-225, 2016

**Geant4 ASSOCIATES**  
Experts in Radiation Simulation



# Human phantoms






Image of Polygon-Surface Reference Korean Male Phantom (PSRK-Man), implemented in Geant4. Courtesy of C.-H. Kim & C. Choi, Hanyang Univ.


# Radiation Environment – model of space station




Courtesy T. Ersmark, KTH Stockholm

# Geant4-DNA applications

Simulation using Geant4-DNA of irradiation of a pBR322 plasmid, including radiolysis



- movie courtesy of V. Stepan (NPI-ASCR/CENBG/CNRS/IN2P3/ESA)



Model of nucleosome created using DnaFabric\*, imported into Geant4 to model irradiation, repair mechanisms.

\* S. Meylan et al, Comp. Phys. Comm. 204 (2016) p159



# Tools for specific applications

based on Geant4

Tools provide specific capabilities for creating setups, measuring

create setup, steer simulation via 'text commands'


output adapted for application-area

[GATE](#) (FR, DE, GR, PL, AT) - PET/SPECT,


[TOPAS](#) (US) - protontherapy

[GAMOS](#) (ES) - for nuclear medicine applications

Developed by external parties - using capabilities of G4 toolkit



Example GATE geometries



**TOPAS** Tool for Particle Simulation

*To use Monte Carlo transport for radiation therapy research in the past, one had to be both an expert in Monte Carlo and an expert in medical physics. With TOPAS, it is sufficient to be an expert in medical physics or biology*


TOPAS has been developed by:  
David Hall  
Bruce Faddegon  
Aimee McNamara  
Harald Paganetti  
Joseph Perl  
Jan Schümann  
Jungwook Shin  
José Ramos

Thank You NIH !!!!

TOPAS supported by the U.S National Institutes of Health under contracts 2R01CA140735-05 and 1 R01 CA187003-01A1 and by TOPAS MC Inc

A 3D visualization of a TOPAS simulation setup, showing a particle beam entering a complex geometry of scintillator crystals and photomultiplier tubes. The text 'TOPAS' is at the top left, and 'Tool for Particle Simulation' is at the top right. The paragraph of text is in the middle, and the list of developers is on the left. The 'Thank You NIH !!!!' text is at the bottom left, and the support information is at the bottom right.

# Flair – fluka advanced interface



Improvements for medical simulations

Process DICOM standard files for radiotherapy purposes

Provides easy-to use tool for treatment plan re-simulation and quantitative comparison

Enables precise description of patient model and beam delivery system

*/fləʊ(r)/* n [U,C] natural or instinctive ability (to do something well,  
to select or recognize what is best, more useful, etc.  
[Oxford Advanced Dictionary of Current English]


is more than a graphical Interface

→ is a complete integrated working environment for FLUKA

Greatly enhanced productivity

→ users focus on their problem rather than on technicalities

In this presentation: a selection of results obtained by the CERN group



3D spatial dose distribution simulated with FLUKA


Importing the RT DOSE with the activity mapping of  $^{68}\text{Ga}$

Simulation of the  $^{68}\text{Ga}$  decays

Very fast setup time


less than a few minutes with a few clicks from the user

Run FLUKA simulations with no programming skills or file editing requirements!






# Sensitivity studies of Monte Carlo TP recalculations



*Proton prostate patient case  
(MedAustron)  
W.Kozłowska PhD*




# Head and Neck case



*Head and Neck case (CNAO)  
W.Kozłowska PhD*

# BioDynaMo: An open-source software framework





a multi-science data-analysis platform, built up around CERN-developed technologies

[www.biodynamo.org](http://www.biodynamo.org)










Courtesy Nicolo Cagno, TU Darmstadt (Germany)

From De Montigny et al., Methods, 2020



Courtesy Jean de Montigny and Roman Bauer





## COVID Airborne Risk Assessment

**CARA - COVID Airborne Risk Assessment calculator**

Simulation name: Office  
Room number: 57/2-002

Virus data: SARS-CoV-2 (Delta VOC)

Room data: Room volume: 100.0  
Floor area: Room floor area (m²)  
Ceiling height: Room ceiling height (m)

Central heating system in use: No Yes  
Location: Melbourne, Victoria, AUS

Ventilation data: Ventilation type: No ventilation Mechanical Natural  
Number of windows: 1  
Height of window: 1.5  
Window type: Sliding / Side-Hung Top or Bottom-Hung  
Width of window: meters  
Opening distance: 1.0  
Windows open: Permanently Periodically: 10.0 120.0  
HEPA filtration: No Yes (m³ / hour)

Event data: Total number of occupants: 5  
Number of infected people: 1  
Activity type: Office  
Exposed person(s) presence: Start: 08:30 Finish: 17:30  
Infected person(s) presence: Start: 08:30 Finish: 17:30  
Which month is the event? December

Activity breaks: Input separate breaks for infected and exposed person(s)  
Lunch break: No Yes  
Start: 12:30 Finish: 13:30  
Coffee breaks: No breaks 2 4  
Duration (minutes): 10  
Coffee breaks are spread evenly throughout the day.


Face masks: Are masks worn when occupants are at workstations? Yes No  
Type of masks used: Type 1 FFP2

Generate report

Developed by CERN personnel to assess the COVID airborne risk in indoor spaces with a risk-based approach.

Includes hourly fluctuations in outdoor temp (GVA data) and detail window modelling for natural ventilation, complex occupancy and ventilation profiles.

Andre Henriquez (CERN)





## Data size

overcome barriers related to data governance and storage  
defining **common principles**

## Data heterogeneity

overcome barriers of data access defining a **global**  
**coordination of open data from multi-domain fields**

## Data analysis

overcome barriers of analysis diversity defining **common pipelines**  
**and approaches**

## Data overload

overcome barriers of excess of information by complying with **results**  
**reproducibility and multi-disciplinary expertise's exchange**



Briefing n° **12**—

## Large particle accelerators

February 2019



Ring segment of a particle accelerator  
© fotonat67 / Adobe Stock

### Summary


- Particle accelerators, like other kinds of “very large research infrastructure” (VLRI), make it possible to manage cutting-edge projects and respond to strategic issues: acquiring knowledge, enhancing scientific attractiveness, preparing for technological breakthroughs, scientific diplomacy, etc.
- CERN, the European particle physics laboratory, currently operates the biggest circular particle accelerator in the world, the LHC, which achieves the highest energies produced to date.
- A decision by the Japanese government is expected regarding an accelerator project, the ILC, proposed since 2007 by the scientific community.
- Thinking on the future European strategy for 2018 and should be presented in spring 2020. It confirms its interest in ILC, this European strategy also states the fact: a possible contribution from Europe must be assessed in terms of scientific return, on the one hand, and societal impact, on the other.

CERN has also had a very strong societal impact via **the creation of the World Wide Web (WWW)** in 1989<sup>(21)</sup> under the leadership of Tim Berners-Lee and his collaborator Roger Cailliau. It was originally a response to researchers’ need to exchange a high volume of data simply and instantaneously for international collaborations. CERN published software


Mr. Cédric Villani, MP (National Assembly), First Vice-Chairman



# From HEP to society: a long and winding road...








Courtesy Luca Bottura (CERN)

On the unreasonable request of high  $J_c$

# The ISEULT whole body 11.7 T MRI magnet

NEUROSPIN: a unique concept  
in neuroscience research




# The ISEULT whole body 11.7 T MRI magnet



The ISEULT magnet - a French-German initiative

Full field of 11.72 teslas achieved on July 18, 2019



First images released  
Oct. 7, 2021

<https://www.cea.fr/presse/Pages/actualites-communiques/sante-sciences-du-vivant/premieres-images-irm-iseult-2021.aspx>



# The Usefulness of Useless Knowledge




ABRAHAM FLEXNER

*With a companion essay by*  
ROBERT DIJKGRAAF

1939!

In the end, utility resulted, but it was never a criterion to which his (*Faraday's, ndr*) ceaseless experimentation could be subjected.

I am not for a moment suggesting that everything that goes on in laboratories will ultimately turn to some unexpected practical use or that an ultimate practical use is its actual justification.



Knowledge Transfer  
*Accelerating Innovation*

Visit [kt.cern](https://kt.cern)